Clik here to view.
MRI/TRUS fusion-guided biopsies and the diagnosis of prostate cancer
An important article by Siddiqui et al. appears in this week’s issue of the Journal of the American Medical Association. It deals with the experience of Dr. Peter Pinto and his colleagues in the...
View ArticleClik here to view.
The Prostate Health Index (phi test) and the need for biopsy
It will come as no great surprise to regular readers that your Sitemaster has been less than enthusiastic to date about the potential of the Prostate Health Index or phi test as a tool for assessment...
View ArticleClik here to view.
Transrectal biopsy and the increasing risk for procedure-related infection
According to a paper presented at the recent meeting of the European Association of Urology in Madrid, Spain, there seems to be a significant and ongoing rise in the global risk for infections...
View ArticleClik here to view.
Prostate biopsies and effects on erectile function post-biopsy
There have long been suggestions that having a prostate biopsy could be associated with at least a temporary decline in erectile function. A new study in BJU International has now shed more light on...
View ArticleClik here to view.
Low serum T and high-risk prostate cancer in Korean men
A group of Korean researchers have poublished data suggesting that — at least in Korean patients — there may be an association between having a low serum testosterone (serum T) level and diagnosis with...
View ArticleClik here to view.
mpMRIs, targeted biopsies, and the accuracy of Gleason grading
A new study that is in press on line in the Journal of Urology addresses, very reasonably, the question of whether using targeted biopsy methods based on multiparametric MRI (mpMRI) data is improving...
View ArticleClik here to view.
New “liquid biopsy” tests of no known value in assessing risk of men for...
The “New” Prostate Cancer InfoLink wishes to very clearly warn its readers about the near to complete lack of any meaningful data — as yet — supporting the use of a new form of test called a “liquid...
View ArticleClik here to view.
Pathway Genomics’ Cancer Intercept test has a problem
Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we...
View ArticleClik here to view.
Risk for ED at up to 12 weeks after a systematic TRUS-guided prostate biopsy
There is nothing very new about the idea that prostate biopsies can affect erectile function in some patients (although we still have very little knowledge of about exactly why this occurs). We have...
View ArticleClik here to view.
The role of liquid biopsies in management of advanced prostate cancer
A newly published paper in Science Translational Medicine has added to our understanding of the future potential of liquid biopsies (e.g., blood, plasma, and similar samples) in the management of...
View ArticleClik here to view.
Liquid biopsies and CTC assays — the scientific progress continues
A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate...
View ArticleClik here to view.
Getting a repeat PSA test prior to biopsy … value now confirmed
For quite a while now The “New” Prostate Cancer InfoLink and many others have been advising men who get a single, somewhat elevated PSA test result to get that test repeated before they make any...
View ArticleClik here to view.
Of liquid biopsies, CTCs, and first-line treatment for mCRPC
A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy...
View ArticleClik here to view.
mpMRIs vs. biopsies for repeat evaluations on active surveillance
A question on the minds of many prostate cancer researchers and clinicians (not to mention their patients) is if and when we may be able to replace repeat systematic prostate biopsies for patients on...
View ArticleClik here to view.
Biopsy rates have fallen; but biopsy complication rates have risen!
A newly published article in European Urology has raised a new issue that should be of significant concern to urologists (and to their patients) in relation to risks associated with the possibility of...
View ArticleClik here to view.
A new urine test to assess risk for prostate cancer?
Apparently a newly developed type of urine test — an RNA-based “urine exosome gene expression assay” — has the potential to differentiate between risk for high-grade prostate cancer (Gleason score ≥ 7)...
View ArticleClik here to view.
mpMRI scans can eliminate the need for prostate biopsy in 27 percent of men...
Another presentation at the ASCO annual meeting yesterday morning came from the PROMIS trial in the UK. The PROMIS trial was a prospective, paired-cohort confirmatory study, designed to provide level...
View ArticleClik here to view.
mpMRIs, MRI/TRUS fusion-guided biopsies, and systematic biopsies in...
A new article in the Journal of Urology has provided us with some initial insight into the value of multiparametric MRIs (mpMRIs) in monitoring progression of patients on active surveillance protocols....
View ArticleClik here to view.
The newly available, urine-based ExoDx Prostate(IntelliScore) test
Back in April this year we reported on the publication of an article in JAMA Oncology that gave information about the development of a new test for risk of clinically significant prostate cancer — a...
View ArticleClik here to view.
How do mpMRI and MRI/TRUS fusion biopsies actually work?
As our regular readers will be well aware, the combination of multiparametric MRI (mpMRI) data with transrectal ultrasound (TRUS)-guided biopsy techniques are rapidly becoming more common in both the...
View Article